Trial Profile
A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary)
- Indications Lymphoma
- Focus Therapeutic Use
- 01 Sep 2023 Results reporting efficacy and safety data published in the Leukemia and Lymphoma
- 29 Nov 2016 Status changed from active, no longer recruiting to discontinued, according toan abstract presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Results (n=4) analysing safety and efficacy presented at the 41st European Society for Medical Oncology Congress.